News

Filter

Current filters:

ResearchAmgen

1 to 9 of 89 results

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

04-02-2015

USA-based biotech major Amgen has reported positive top-line data from a Phase III study of its biosimilar…

ABP 501adalimumabAmgenAnti-Arthritics/RheumaticsBiosimilarsHumiraResearchUSA

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

16-01-2015

USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies…

AmgenBiotechnologyOncologyResearchVectibix

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

Boehringer Ingelheim, Janssen and Novartis among partners teaming up for Alzheimer's research

15-01-2015

German family-owned drug major Boehringer Ingelheim is one of 35 partners from industry and academia…

AmgenBoehringer IngelheimEuropeJanssenNeurologicalNovartisPharmaceuticalResearch

Amgen to collaborate with University of Texas on BiTE technology

Amgen to collaborate with University of Texas on BiTE technology

13-01-2015

US biotech major Amgen is to collaborate with the MD Anderson Cancer Center at the University of Texas…

AmgenBiotechnologyOncologyResearchUSA

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

Amgen and Kite Pharma collaborate on CAR T cell therapies

05-01-2015

Kite Pharma has announced a strategic research collaboration and license agreement with US biotech giant…

AmgenBiotechnologyKite PharmaLicensingOncologyResearch

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

08-12-2014

USA-based Amgen and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE…

AmgenBiotechnologyDexamethasoneKyprolisOncologyOnyx PharmaceuticalsResearchRevlimid

1 to 9 of 89 results

Back to top